Opinion|Videos|May 2, 2024
Toxicity Considerations and Treatment Decisions in CRC
Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The FDA has granted fast track designation to varsetatug masetecan for relapsed/refractory metastatic colorectal cancer.
SYS6090, a first-in-class PD-1/IL-15 bispecific fusion protein, earned fast track status for MSS/pMMR metastatic colorectal cancer that has progressed on standard systemic therapy.
The FDA set a target action date of February 2027 for the dostarlimab-gxly sBLA in dMMR/MSI-H locally advanced rectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5